Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Outset Medical, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
2.01
15.1
49.9
103
115
130
114
119
Cost of revenue
8.12
32.9
63
95
97.5
101
75.1
72.7
Gross profit
-6.12
-17.8
-13
7.61
17.8
29
38.6
46.8
Research and development
22.9
23.3
28.9
36.7
48.9
57.3
38.4
21.2
Selling and marketing
11.3
20.3
45.1
65.1
89.5
96.2
70
54.4
General and administrative
6.25
8.92
30.5
36.3
40.5
45.2
43.5
37.9
Operating expenses
40.4
52.5
104
138
179
199
152
113
Operating income
-46.6
-70.3
-117
-131
-161
-170
-113
-66.7
Interest expense
4.64
4.26
2.89
1.72
3.57
12.7
23.9
14
Other non-operating income
1.71
2.49
0.53
0.5
3.29
10.2
9.76
7.41
Pre-tax income
-49.8
-68.3
-121
-132
-163
-172
-127
-80.9
Income tax
0.03
0.02
0
0.2
0.3
0.52
0.49
0.72
Net income
-49.8
-68.3
-121
-132
-163
-173
-128
-81.7
EBITDA
-45.5
-68.8
-114
-125
-156
-164
-108
-62.4
EPS, basic
-1,514.00
-1,496.00
-72.86
-43.42
-50.78
-52.28
-36.96
-5.37
EPS, diluted
-1,514.00
-1,496.00
-72.86
-43.42
-50.78
-52.28
-36.96
-5.37
Shares, basic (weighted)
0.05
0.06
0
0
0
0
0
0.02
Shares, diluted (weighted)
0.05
0.06
0
0
0
0
0
0.02
Balance sheet
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
36.9
295
182
73.2
68.5
124
35
Short-term investments
33.2
19.9
157
214
135
34.7
134
Receivables
3.91
6.47
25.6
28.1
33
35.6
28.3
Inventory
4.6
18.4
39.2
51.5
49.2
59.4
47.6
Other current assets
1.06
6.19
5.53
6.6
5.7
4.53
6
Total current assets
79.6
346
410
374
291
258
251
Property, plant and equipment
7.9
15
13
15.9
13.3
8.13
4.67
Lease right-of-use assets
8.25
7.23
6.12
5.38
3.94
4.8
Other non-current assets
0.08
1.36
0.16
1.17
0.61
2.17
0.32
Total assets
88.4
404
463
400
314
276
264
Accounts payable
4.96
4.95
1.76
0.6
5.83
3.86
0.55
Deferred revenue
0.88
3.2
6.34
8.66
11.7
12.8
13.8
Short-term debt
7.5
2.03
2.03
4.75
Total current liabilities
24.9
36.7
51.7
51.9
55.3
45.4
37.6
Long-term debt
21.6
29.7
29.8
96.3
130
197
96.2
Lease liabilities
8.04
6.89
5.58
4.48
2.68
3.27
Total liabilities
51.1
75.2
89.4
154
191
249
138
Total debt
29.1
29.7
29.8
96.3
130
197
96.2
Paid-in capital
0.36
823
1,000
1,035
1,085
1,116
1,298
Retained earnings
-373
-494
-626
-789
-962
-1,090
-1,171
Other comprehensive income
0.02
0
-0.18
-0.56
0.07
0.04
0.17
Shareholders' equity
-288
-372
329
374
246
123
26.8
127
Total equity
-288
-372
329
374
246
123
26.8
127
Total liabilities and equity
88.4
404
463
400
314
276
264
Shares outstanding
0.06
2.84
3.14
3.23
50.3
3.53
18.2
Cash flow statement
FY2018
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-49.8
-68.3
-121
-132
-163
-173
-128
-81.7
Depreciation and amortization
1.07
1.48
3.16
5.16
5.17
5.81
5.73
4.34
Stock-based compensation
0.79
0.88
21.4
17.4
27.2
38.6
29.4
15.6
Change in receivables
-0.55
-2.89
-2.57
-19.1
-2.51
-5.09
-5.01
3.78
Change in inventory
-2.21
-5.02
-16.3
-22
-14.7
1.65
-10.9
11.8
Change in payables
2.68
0.8
0.74
-3.07
-1.28
5.31
-1.95
-3.29
Cash from operations
-46.4
-70.3
-99
-130
-146
-131
-116
-46.3
Capital expenditures
-1.77
-3.29
-9.08
-3.11
-8.33
-3.44
-0.91
-0.8
Purchases of investments
-132
-91.9
-32.9
-178
-261
-172
-157
-222
Sales and maturities of investments
169
45.9
39
203
259
261
125
Cash from investing
-68.8
74.3
3.95
-143
-66.3
83
104
-97.7
Debt issued
29.6
0
96.1
33.2
66.5
98.3
Stock issued
0.31
0.36
255
149
0
0
Cash from financing
135
0.25
386
160
72.9
43.7
67.9
55.5
Net change in cash
19.7
4.25
291
-113
-139
-4.7
55.5
-88.5
Free cash flow
-48.2
-73.6
-108
-133
-154
-135
-117
-47.1
Interest paid
3.29
3.35
3.27
1.15
3.19
10.8
20.7
15.6
Income taxes paid
0.01
0.04
0.02
0.08
0.39
0.49
0.59
0.45
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.05 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
41.8%
Gross profit / revenue.
Operating margin
-56.1%
Operating income / revenue.
EBITDA margin
-53.2%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-62.3%
Pre-tax income / revenue.
Net margin
-63.1%
Net income / revenue.
FCF margin
-33.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-32.5%
Cash from operations / revenue.
Return on equity (ROE)
-77.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-30.7%
Net income / average total assets.
Return on invested capital (ROIC)
-32.8%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
18.3%
Research and development expense / revenue.
Stock-based pay / revenue
13.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.5%
Capital expenditures / revenue.
D&A / revenue
2.8%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
5.1%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
1.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
19.1%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
21.2%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
37.9%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
373.4%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-19.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-17.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-4.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-12.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-8.1%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
339.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
68.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
69.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
5.19x
Current assets / current liabilities.
Quick ratio
4.02x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.35x
(Cash + short-term investments) / current liabilities.
Debt / equity
1.01x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
40.3%
Total debt / total assets.
Liabilities / assets
60.3%
Total liabilities / total assets.
Net debt
-$49.5M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$3,990.00
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$6,327.00
Revenue / diluted weighted shares.
FCF per share
-$2,088.00
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2,058.00
Cash from operations / diluted weighted shares.
Book value per share
$5.13
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.49x
Market cap / revenue.
P/B
0.60x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.60x
Market cap / tangible book value, when positive.
EV/Sales
0.07x
Enterprise value / revenue.
FCF yield
-67.8%
Free cash flow / market cap.
Earnings yield
-129.6%
Net income / market cap (the inverse of P/E).
What was Outset Medical, Inc.'s revenue in fiscal 2025?
Outset Medical, Inc. reported revenue of $119.5M for fiscal 2025, 5.1% higher than the year before.
Was Outset Medical, Inc. profitable in fiscal 2025?
No. It reported a net loss of $81.7M.
How much free cash flow did Outset Medical, Inc. generate in fiscal 2025?
Cash from operations of $46.3M minus capital expenditures of $798.0K left free cash flow of -$47.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.